NOVATO, Calif., Feb. 09, 2017 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Thursday, February 16, 2017 at 5pm ET to discuss fourth quarter and full year 2016 financial results and provide a corporate update.
The live and replayed webcast of the call will be available through the company’s website at http://ir.ultragenyx.com/events.cfm. To participate in the live call by phone, dial 855-797-6910 (USA) or 262-912-6260 (international) and enter the passcode 67687697. The replay of the call will be available for one year.
About Ultragenyx
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc. Investors & Media Ryan Martins 844-758-7273


Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 



